SG11202103340PA - 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease - Google Patents
7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's diseaseInfo
- Publication number
- SG11202103340PA SG11202103340PA SG11202103340PA SG11202103340PA SG11202103340PA SG 11202103340P A SG11202103340P A SG 11202103340PA SG 11202103340P A SG11202103340P A SG 11202103340PA SG 11202103340P A SG11202103340P A SG 11202103340PA SG 11202103340P A SG11202103340P A SG 11202103340PA
- Authority
- SG
- Singapore
- Prior art keywords
- octan
- azabicyclo
- pyrrolo
- triazol
- alzheimer
- Prior art date
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212199 | 2018-12-13 | ||
| PCT/EP2019/084538 WO2020120521A1 (en) | 2018-12-13 | 2019-12-11 | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103340PA true SG11202103340PA (en) | 2021-04-29 |
Family
ID=64665266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103340PA SG11202103340PA (en) | 2018-12-13 | 2019-12-11 | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220056036A1 (en) |
| EP (2) | EP3894411B1 (en) |
| JP (1) | JP7566745B2 (en) |
| KR (1) | KR20210102900A (en) |
| CN (2) | CN113179641B (en) |
| AR (1) | AR116906A1 (en) |
| AU (1) | AU2019395774A1 (en) |
| BR (1) | BR112021009443A2 (en) |
| CA (1) | CA3117870A1 (en) |
| CL (1) | CL2021001547A1 (en) |
| CO (1) | CO2021006837A2 (en) |
| CR (1) | CR20210305A (en) |
| DK (1) | DK3894411T3 (en) |
| FI (1) | FI3894411T3 (en) |
| IL (2) | IL283823B2 (en) |
| LT (1) | LT3894411T (en) |
| MA (1) | MA54447A (en) |
| MX (1) | MX2021006761A (en) |
| PE (1) | PE20211776A1 (en) |
| PL (1) | PL3894411T3 (en) |
| PT (1) | PT3894411T (en) |
| RS (1) | RS65821B1 (en) |
| SG (1) | SG11202103340PA (en) |
| TW (1) | TWI831892B (en) |
| WO (1) | WO2020120521A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703763B2 (en) * | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| WO2017042114A1 (en) | 2015-09-09 | 2017-03-16 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| CN108137579B (en) * | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | Bridged piperidine derivatives |
| WO2018001918A1 (en) * | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines as gamma-secretase modulators |
| WO2018083050A1 (en) * | 2016-11-01 | 2018-05-11 | F. Hoffmann-La Roche Ag | Bicyclic heteroaryl derivatives |
| CN109790149B (en) | 2016-11-08 | 2022-05-17 | 豪夫迈·罗氏有限公司 | Phenoxytriazoles |
| RU2757276C2 (en) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Methods for the treatment of cochlear synaptopathy |
| US11370802B2 (en) | 2018-01-22 | 2022-06-28 | Hoffmann-La Roche, Inc. | Triazolo-azepine derivatives |
-
2019
- 2019-12-11 KR KR1020217017774A patent/KR20210102900A/en unknown
- 2019-12-11 JP JP2021533563A patent/JP7566745B2/en active Active
- 2019-12-11 AU AU2019395774A patent/AU2019395774A1/en active Pending
- 2019-12-11 MX MX2021006761A patent/MX2021006761A/en unknown
- 2019-12-11 SG SG11202103340PA patent/SG11202103340PA/en unknown
- 2019-12-11 PE PE2021000726A patent/PE20211776A1/en unknown
- 2019-12-11 PL PL19824250.5T patent/PL3894411T3/en unknown
- 2019-12-11 EP EP19824250.5A patent/EP3894411B1/en active Active
- 2019-12-11 PT PT198242505T patent/PT3894411T/en unknown
- 2019-12-11 DK DK19824250.5T patent/DK3894411T3/en active
- 2019-12-11 CN CN201980076253.8A patent/CN113179641B/en active Active
- 2019-12-11 CN CN202311792520.6A patent/CN117946116A/en active Pending
- 2019-12-11 US US17/413,413 patent/US20220056036A1/en active Pending
- 2019-12-11 CA CA3117870A patent/CA3117870A1/en active Pending
- 2019-12-11 IL IL283823A patent/IL283823B2/en unknown
- 2019-12-11 EP EP24177200.3A patent/EP4424370A2/en active Pending
- 2019-12-11 CR CR20210305A patent/CR20210305A/en unknown
- 2019-12-11 LT LTEPPCT/EP2019/084538T patent/LT3894411T/en unknown
- 2019-12-11 MA MA054447A patent/MA54447A/en unknown
- 2019-12-11 RS RS20240883A patent/RS65821B1/en unknown
- 2019-12-11 WO PCT/EP2019/084538 patent/WO2020120521A1/en active Application Filing
- 2019-12-11 FI FIEP19824250.5T patent/FI3894411T3/en active
- 2019-12-11 IL IL310081A patent/IL310081A/en unknown
- 2019-12-11 BR BR112021009443-1A patent/BR112021009443A2/en unknown
- 2019-12-12 AR ARP190103631A patent/AR116906A1/en unknown
- 2019-12-12 TW TW108145480A patent/TWI831892B/en active
-
2021
- 2021-05-24 CO CONC2021/0006837A patent/CO2021006837A2/en unknown
- 2021-06-11 CL CL2021001547A patent/CL2021001547A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL283823B2 (en) | 2024-07-01 |
| EP4424370A2 (en) | 2024-09-04 |
| CL2021001547A1 (en) | 2021-12-24 |
| BR112021009443A2 (en) | 2021-08-17 |
| IL310081A (en) | 2024-03-01 |
| EP3894411A1 (en) | 2021-10-20 |
| TW202039499A (en) | 2020-11-01 |
| TWI831892B (en) | 2024-02-11 |
| RS65821B1 (en) | 2024-09-30 |
| PT3894411T (en) | 2024-08-08 |
| IL283823A (en) | 2021-07-29 |
| MA54447A (en) | 2022-03-23 |
| IL283823B1 (en) | 2024-03-01 |
| CN113179641A (en) | 2021-07-27 |
| FI3894411T3 (en) | 2024-08-15 |
| CA3117870A1 (en) | 2020-06-18 |
| LT3894411T (en) | 2024-08-26 |
| US20220056036A1 (en) | 2022-02-24 |
| CN117946116A (en) | 2024-04-30 |
| JP2022513466A (en) | 2022-02-08 |
| CO2021006837A2 (en) | 2021-06-10 |
| MX2021006761A (en) | 2021-07-15 |
| CR20210305A (en) | 2021-07-20 |
| DK3894411T3 (en) | 2024-08-19 |
| EP3894411B1 (en) | 2024-06-19 |
| JP7566745B2 (en) | 2024-10-15 |
| PE20211776A1 (en) | 2021-09-08 |
| CN113179641B (en) | 2024-01-02 |
| PL3894411T3 (en) | 2024-10-07 |
| AR116906A1 (en) | 2021-06-23 |
| KR20210102900A (en) | 2021-08-20 |
| AU2019395774A1 (en) | 2021-04-08 |
| WO2020120521A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266170A (en) | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | |
| MX2017005940A (en) | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders. | |
| IL286912A (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| EP3107914B8 (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| WO2015095337A3 (en) | PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT | |
| IL275781A (en) | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease | |
| IL283149A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| IL285445A (en) | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders | |
| MX2018012207A (en) | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders. | |
| MX2018012211A (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders. | |
| MX2018012208A (en) | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders. | |
| WO2016016380A8 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| IL267801B1 (en) | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds | |
| IL286870A (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1 ,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease | |
| ZA202100259B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| EP3463372A4 (en) | Fused bicyclic compounds for the treatment of disease | |
| IL283823A (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| SG11202002692XA (en) | Azabicyclo and diazepine derivatives for treating ocular disorders | |
| IL291335A (en) | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1 ,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease | |
| IL253427A0 (en) | Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis |